We’re pleased to share that DrugPatentWatch has been recognized as the Best Biopharmaceuticals Commercial Business Intelligence Platform by Global Health
DrugPatentWatch Ranked Best Biopharmaceuticals Commercial Business Intelligence Platform Read Post »
A deep-dive strategy guide for pharmaceutical IP teams, portfolio managers, R&D leads, and institutional investors navigating the full lifecycle of
New DrugPatentWatch module connects excipients and drug patents In response to user requests, DrugPatentWatch has added a new database of
Connecting Excipients with Drug Patents – New DrugPatentWatch module Read Post »
DrugPatentWatch was featured in a recent article by Inc. Magazine. In their coverage of Mark Cuban’s new pharma company, they cited
DrugPatentWatch featured in Inc Magazine Read Post »
1. Why Generic Drug Market Entry Demands a Different Analytical Framework Generic pharmaceutical market entry is not a standard product
I. Why This Document Exists Every blockbuster drug that has generated a billion-dollar revenue stream in the past three decades
The $230 Billion Subsidy: How Government Patent Data Drives Biopharma IP Strategy Read Post »
In the early months of the pandemic, when much of the economy was idling, an unusual silence fell over another
Bloomberg and Drug PatentWatch: A “Perfect Storm” Affecting Generic Drugs Read Post »
Part I: US Pharmaceutical Market — Scale, Structural Drivers, and the 2025 Inflection Point Market Size Reality Check: Reconciling Competing
Check out this Bloomberg Law article where DrugPatentWatch shows how the number of patent challenges is increasing, while the number of
DrugPatentWatch and Bloomberg: Are there too many generic patent challenges? Read Post »
Sign in or create a free account to read this DrugPatentWatch article
